|
| Press Releases |
|
 |
|
| Thursday, October 17, 2024 |
|
|
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. more info >> |
|
| Tuesday, October 15, 2024 |
|
|
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. more info >> |
|
| Wednesday, October 9, 2024 |
|
|
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) Zepbound (tirzepatide) in an oral dose format. more info >> |
|
| Tuesday, October 8, 2024 |
|
|
Lexaria Updates Current GLP-1 Market |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements. more info >> |
|
| Tuesday, October 1, 2024 |
|
|
Lexaria Appoints Michael Shankman as Chief Financial Officer |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations. more info >> |
|
| Friday, September 27, 2024 |
|
|
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) tirzepatide in an oral dose format. more info >> |
|
| Thursday, September 5, 2024 |
|
|
Lexaria Releases Strategic Letter from the Outgoing CEO |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer ("CEO") Chris Bunka as a strategic update to all stakeholders. more info >> |
|
|
Lexaria Welcomes Industry Veteran as New CEO |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that Chris Bunka, Chief Executive Officer ("CEO") of the Company, is stepping aside for the appointment of Richard Christopher as the new CEO, effective August 31, 2024. more info >> |
|
| Tuesday, September 3, 2024 |
|
|
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into a Material Transfer Agreement with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting. more info >> |
|
| Thursday, August 29, 2024 |
|
|
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus Oral Capsules |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
金沢大とエーザイ、レカネマブがアルツハイマー病の病態進行を抑制するメカニズムの一端を解明
Jan 7, 2025 09:00: JST
|
|
|
Spectral Achieves Major Patent Milestone Related to Quantum Computing
Jan 6, 2025 23:37: JST
|
|
|
2025 Toys & Games Fair, Baby Products Fair, Stationery & School Supplies Fair open today
Jan 6, 2025 22:40 HKT/SGT
|
|
|
Spectral Achieves Major Patent Milestone Related to Quantum Computing
Jan 6, 2025 22:37 HKT/SGT
|
|
|
AI Connect to Launch Revolutionary AI Agent, Redefining Financial and Technological Innovation
Jan 6, 2025 15:00: JST
|
|
|
Toyota to Share Progress on Woven City at CES 2025
Jan 6, 2025 15:49 JST
|
|
|
Mazda to build Module Pack Plant for Cylindrical Lithium-ion Batteries for Automotive Use in Iwakuni City, Yamaguchi Prefecture
Jan 6, 2025 15:36 JST
|
|
|
AI Connect to Launch Revolutionary AI Agent, Redefining Financial and Technological Innovation
Jan 6, 2025 14:00 HKT/SGT
|
|
|
泛遠國際附屬收購美國物流公司30%股權
Jan 6, 2025 12:16 HKT/SGT
|
|
|
泛远国际附属收购美国物流公司30%股权
Jan 6, 2025 12:10 HKT/SGT
|
|
|
Celebrate Chinese New Year 2025 with Spritzer: Embrace Heartfelt & Refreshing Moments
Jan 6, 2025 12:00 HKT/SGT
|
|
|
美高域攜手蓋睿科技 AI賦能助力打造香港醫療新模式
Jan 6, 2025 08:50 HKT/SGT
|
|
|
美高域携手盖睿科技 AI赋能助力打造香港医疗新模式
Jan 6, 2025 08:50 HKT/SGT
|
|
|
Galaxy Payroll Group Limited and People Intelligence Singapore Pte. Ltd. Announce Strategic Partnership
Jan 3, 2025 20:41 JST
|
|
|
蜜雪冰城擬香港上市 業績如虹釋放飛輪效應
Jan 3, 2025 16:27 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
